Literature DB >> 2895838

Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. ISIS-1 (First International Study of Infarct Survival) Collaborative Group.

.   

Abstract

In a large randomised trial of early beta-blockade in acute myocardial infarction (ISIS-1), almost all the reduction in mortality associated with the use of atenolol occurred on the day of admission or on the subsequent day. To help determine the mechanisms that might be responsible for this retrospective observation, case notes were obtained for British, Irish, and Scandinavian patients who died during this early period. Of 217 early deaths adequate records were available for 193 (79 allocated atenolol and 114 allocated control). In the atenolol group, necropsy had shown cardiac rupture in 5 patients, and a further 15 in whom necropsy had not been done had had electro-mechanical dissociation (total, 20 early deaths from these causes); among control patients the corresponding numbers were 17 and 37 (total, 54 such deaths). Electro-mechanical dissociation was probably a manifestation of acute rupture, and the observed difference in the numbers with this complication was responsible for much of the difference in early mortality. There was a slightly higher incidence of fatal ventricular fibrillation and aortic dissection in the control group, and of bradycardia/asystole in the atenolol group. The data did not indicate any substantial contribution from mechanisms such as limitation of infarct size or prevention of reinfarction or cardiac arrest.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2895838

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  17 in total

1.  Current and Practical Management of Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 2.  Beta-adrenergic blocking drugs as antifibrillatory agents.

Authors:  Michael J Reiter
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

3.  [Application of the current resuscitation guidelines 2005. Case report of successful cardiopulmonary resuscitation].

Authors:  M Eppinger; G Flury; V Wenzel; J Koppenberg
Journal:  Anaesthesist       Date:  2007-11       Impact factor: 1.041

Review 4.  Risk-benefit assessment of antiarrhythmic drugs. An epidemiological perspective.

Authors:  L Friedman; E Schron; S Yusuf
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

5.  beta-Adrenergic receptor blockers and heart failure risk after myocardial infarction: a critical review.

Authors:  Robert H Neumayr; Paul J Hauptman
Journal:  Curr Heart Fail Rep       Date:  2009-12

6.  Preventive treatment of postinfarction heart rupture.

Authors:  J T Beranek
Journal:  Cardiovasc Drugs Ther       Date:  1995-02       Impact factor: 3.727

Review 7.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 8.  [Acute coronary syndrome in the prehospital phase].

Authors:  J-H Schiff; H R Arntz; B W Böttiger
Journal:  Anaesthesist       Date:  2005-10       Impact factor: 1.041

Review 9.  Treatment for survivors of acute myocardial infarction: what have we learned from large intervention trials?

Authors:  D G Julian
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

10.  Neurocardiology shows that the central, not peripheral, action of propranolol reduces mortality following acute coronary artery occlusion in the conscious pig.

Authors:  J E Skinner
Journal:  Integr Physiol Behav Sci       Date:  1991 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.